Voorbeelden van het gebruik van Lacosamide in het Engels en hun vertalingen in het Nederlands
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Each ml of syrup contains 10 mg lacosamide.
Lacosamide has a low protein binding of less than 15.
Ml Vimpat syrup contains 10 mg lacosamide.
Lacosamide is less than 15% bound to plasma.
Bottle of 200 ml contains 2,000 mg lacosamide.
Lacosamide does not inhibit or induce the enzyme CYP2C19 in vivo.
Vial of 20 ml contains 200 mg lacosamide.
Lacosamide is effectively removed from plasma by haemodialysis.
Each film-coated tablet contains 100 mg lacosamide.
The metabolism of lacosamide has not been completely characterised.
Vimpat 10 mg/ ml solution for infusion Lacosamide.
Lacosamide Pain UCB Pharma contains the active substance lacosamide.
One tablet of Vimpat 50 mg contains 50 mg lacosamide.
The experience with lacosamide in elderly patients with epilepsy is limited.
Each ml of solution contains 10 mg lacosamide.
Lacosamide did not affect the single-dose pharmacokinetics of omeprazole.
What Vimpat contains The active substance is lacosamide.
Lactation It is unknown whether lacosamide is excreted in human breast milk.
Ml Vimpat solution for infusion contains 10 mg lacosamide.
Data generally suggest that lacosamide has a low interaction potential.
There is no specific antidote for overdose with lacosamide.
Lacosamide plasma concentrations were not affected by carbamazepine and by valproic acid.
Vimpat is a medicine containing the active substance lacosamide.
Lacosamide is also thought to be involved in the development of nerve cells that have been damaged.
Vial of 20 ml solution for infusion contains 200 mg lacosamide.
The pharmacokinetics of lacosamide has not been evaluated in severely hepatic impaired patients see section 5.2.
There was no clinically relevant interaction between lacosamide and metformin.
Elimination Lacosamide is primarily eliminated from the systemic circulation by renal excretion and biotransformation.
There is limited clinical experience with lacosamide overdose in humans.
For precautionary measures, breast-feeding should be discontinued during treatment with lacosamide.